Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the high short interest stocks to buy right now. On November 21, H.C.

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, announced today ...

They haven't peaked yet.

The company's worst days might be behind it.

Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Galmed Pharmaceuticals ( ($GLMD) ) has shared an update. On December 4, 2025, Galmed Pharmaceuticals announced the grant of a new use patent in ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor ...

CONSHOHOCKEN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic ...

Retail traders on Stocktwits drove a surge in takeover speculation amid Madrigal’s strong momentum around its liver-disease drug Rezdiffra. ・Fresh analyst target hikes followed new two-year clinical ...

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global equities continue to ...

Nicotine addiction remains one of the most persistent public health challenges worldwide, driven by changes in the brain that reinforce repeated use and make quitting extremely difficult. For decades, ...